European Experience on the Practical Use of Levosimendan in Patients with Acute Heart Failure Syndromes

This publication has 27 references indexed in Scilit:

• Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients
  International Journal of Cardiology, 2005
• Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone
  The American Journal of Cardiology, 2004
• P2166 Levosimendan is efficacious in acute heart failure independent of renal function
  European Heart Journal, 2003
• Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
  European Heart Journal, 2002
• Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial
  The Lancet, 2002
• Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure
  Journal of the American College of Cardiology, 2000
• Myocardial efficiency during levosimendan infusion in congestive heart failure
  Clinical Pharmacology & Therapeutics, 2000
• Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure
  Circulation, 2000
• Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes
  European Journal of Pharmacology, 1997
• Troponin C-mediated calcium sensitization by levosimendan accelarates the proportional development of isometric tension
  Journal of Molecular and Cellular Cardiology, 1995